Octagon Capital Advisors L.P. is an investment fund managing more than $375 million ran by Justin Hirsch. There are currently 20 companies in Mr. Hirsch’s portfolio. The largest investments include Apellis Pharmaceuticals Inc and Arcus Biosciences Inc, together worth $184 million.
As of 8th August 2022, Octagon Capital Advisors L.P.’s top holding is 2,583,059 shares of Apellis Pharmaceuticals Inc currently worth over $117 million and making up 31.2% of the portfolio value.
Relative to the number of outstanding shares of Apellis Pharmaceuticals Inc, Octagon Capital Advisors L.P. owns more than approximately 0.1% of the company.
In addition, the fund holds 2,669,974 shares of Arcus Biosciences Inc worth $67.7 million, whose value fell 8.4% in the past six months.
The third-largest holding is Chinook Therapeutics worth $44.6 million and the next is Horizon Therapeutics Pub L worth $26.3 million, with 330,000 shares owned.
Currently, Octagon Capital Advisors L.P.'s portfolio is worth at least $375 million. The total portfolio value may be much higher due to cash
assets that are not publicly disclosed such as fixed income, real estate, or cash equivalents.
The Octagon Capital Advisors L.P. office and employees reside in New York, New York. According to the last 13-F report filed with the SEC, Justin Hirsch serves as the Chief Compliance Officer and Chief Financial Officer at Octagon Capital Advisors L.P..
In the most recent 13F filing, Octagon Capital Advisors L.P. revealed that it had opened a new position in
Mereo BioPharma plc and bought 1,000,000 shares worth $1.12 million.
This means they effectively own approximately 0.1% of the company.
Mereo BioPharma plc makes up
0.4%
of the fund's Health Care sector allocation and has decreased its share price by approximately 0.1% in the past year.
The investment fund also strengthened its position in Apellis Pharmaceuticals Inc by buying
243,000 additional shares.
This makes their stake in Apellis Pharmaceuticals Inc total 2,583,059 shares worth $117 million.
Apellis Pharmaceuticals Inc dropped approximately 0.1% in the past year.
On the other hand, there are companies that Octagon Capital Advisors L.P. is getting rid of from its portfolio.
Octagon Capital Advisors L.P. closed its position in iTeos Therapeutics on 15th August 2022.
It sold the previously owned 450,776 shares for $14.5 million.
Justin Hirsch also disclosed a decreased stake in Stoke Therapeutics by approximately 0.1%.
This leaves the value of the investment at $10.1 million and 763,456 shares.
The two most similar investment funds to Octagon Capital Advisors L.P. are Browning West L.P. and Stonnington Group. They manage $375 million and $375 million respectively.
Octagon Capital Advisors L.P.’s portfolio is diversified across 2 sectors.
Currently, their heaviest sector is Health Care — making up 83.7% of
the total portfolio value.
The fund focuses on investments in the United States as
60.0% of the portfolio companies
are based in the United States.
The majority of the companies in the fund’s portfolio are small-cap stocks.
Stocks with a size of more than $100 million in market cap make up
5% of the total holdings value.
On the other hand, large-cap stocks make up only approximately 0.1% of the portfolio.
The average market cap of the portfolio companies is close to $1.54 billion.
These positions were updated on August 15th based on the fund’s latest 13F filing. Quickly find out what the most recently closed or increased positions are.
| Security | Shares Owned | Value | Allocation |
|---|---|---|---|
| Apellis Pharmaceuticals Inc |
10.38%
2,583,059
|
$116,806,000 | 31.17% |
| Arcus Biosciences Inc |
7.23%
2,669,974
|
$67,657,000 | 18.06% |
| Chinook Therapeutics, Inc. |
88.14%
2,551,703
|
$44,629,000 | 11.91% |
| Horizon Therapeutics Pub L |
230.00%
330,000
|
$26,321,000 | 7.02% |
| Gossamer Bio, Inc. |
7.61%
2,758,069
|
$23,085,000 | 6.16% |
| Celldex Therapeutics Inc. |
No change
761,398
|
$20,527,000 | 5.48% |
| Spdr Ser Tr |
336.20%
243,400
|
$18,077,000 | 4.82% |
| iTeos Therapeutics, Inc. |
Closed
450,776
|
$14,506,000 | |
| Stoke Therapeutics, Inc. |
6.15%
763,456
|
$10,085,000 | 2.69% |
| BridgeBio Pharma Inc |
58.82%
933,743
|
$8,478,000 | 2.26% |
| Vera Therapeutics Inc |
No change
575,000
|
$7,826,000 | 2.09% |
| Arvinas Inc |
No change
178,500
|
$7,513,000 | 2.01% |
| Surface Oncology Inc |
Closed
2,300,000
|
$6,762,000 | |
| Dyne Therapeutics, Inc. |
Closed
525,284
|
$5,064,000 | |
| Avidity Biosciences, Inc. |
No change
321,641
|
$4,673,000 | 1.25% |
| 4d Molecular Therapeutics In |
59.62%
632,745
|
$4,417,000 | 1.18% |
| Keros Therapeutics, Inc. |
55.25%
152,249
|
$4,207,000 | 1.12% |
| I-Mab |
80.96%
199,876
|
$2,259,000 | 0.60% |
| Prometheus Biosciences Inc |
No change
80,000
|
$2,258,000 | 0.60% |
| Immunovant Inc |
60.74%
579,061
|
$2,258,000 | 0.60% |
| Century Therapeutics Inc |
60.50%
260,000
|
$2,184,000 | 0.58% |
| Mereo BioPharma Group plc |
Opened
1,000,000
|
$1,120,000 | 0.30% |
| Omega Therapeutics Inc |
Closed
176,470
|
$1,101,000 | |
| Connect Biopharma Hldgs Ltd |
Closed
279,921
|
$845,000 | |
| Ambrx Biopharma Inc. |
17.80%
122,800
|
$325,000 | 0.09% |
| No transactions found | |||
| Showing first 500 out of 25 holdings | |||